Russian Heart Failure Journal 2011year Effect of therapy with levothyroxine on clinical, hemodynamic and neurohumoral status of patients with heart failure in combination with subclinical hypothyroidism


To access this material please log in or register

Register Authorize
2011/

Effect of therapy with levothyroxine on clinical, hemodynamic and neurohumoral status of patients with heart failure in combination with subclinical hypothyroidism

Blankova Z. N., Seredinina E. M., Ageev F. T.
Federal State Budgetary Institution, “Russian Cardiology Research and Production Complex” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: hemodynamics, hypothyroidism, the clinical picture, levothyroxine, neurohumoral status, CHF

DOI: 10.18087/rhfj.2011.1.1457

Background. CHF flow in terms of subclinical hypothyroidism (SH) is deteriorating even with a small increase of thyroid-stimulating hormone (TSH) level. Correction of thyroid status in these patients can improve outcomes of heart failure. Objective. To study the effect of levothyroxine therapy on clinical, hemodynamic and neurohumoral status in patients with chronic heart failure with preserved systolic function (CHF-PSF) in combination with SH. Materials and methods. The study included 43 patients with CHF I–II FC with PSF in combination with the SH. They were randomized into two groups: Group I received standard therapy for CHF, II group – standard therapy + levothyroxine. At baseline and after treatment period completion all patients underwent clinical and instrumental exa­mination including echocardiography, Holter ECG monitoring, analysis (serum level of TSH,  triiodothyronine, tetraiodothyronine and N-terminal fragment of the prohormone brain-type natriuretic peptide – NT-proBNP). Results. Hormone replacement therapy in patients with CHF-PSF and SH significantly improved their clinical and functional status, quality of life, parameters of diastolic function. NT-proBNP level in patients with CHF in combination with SH can not be a reliable factor of CHF severity.
  1. Rodondi N, Newman AB, Vittinghoff E et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2005 Nov 28;165 (21):2460–2466.
  2. Iacoviello M, Guida P, Guastamacchia E et al. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr Pharm Des. 2008;14 (26):2686–2692.
  3. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid disease prevalence study. Arch Intern Med. 2000;160 (4):526–534.
  4. Wilson S, Parle JV, Roberts LM et al.; Birmingham Elderly Thyroid Study Team. Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. J Clin Endocrinol Metab. 2006;91 (12):4809–4816.
  5. Rush J, Danzi S, Klein I. Role of thyroid disease in the development of statin-induced myopathy. The Endocrinologist. 2006;16:279–285.
  6. Rodondi N, den Elzen WP, Bauer DC et al. Thyroid Studies Collaboration Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304 (12):1365–1374.
  7. Razvi S, Ingoe L, Keeka G et al. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial J Clin Endocrinol Metab. 2007;92 (5):1715–1723.
  8. Arinc H, Gunduz H, Tamer A et al. Tissue Doppler echocardiography in evaluation of cardiac effects of subclinical hypothyroidism. Int J Cardiovasc Imaging. 2006;22 (2):187–189.
  9. Christ-Crain M, Morgenthaler NG, Meier C et al. Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states. Swiss Med Wkly. 2005;135 (37-38):549–554.
  10. Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev. 2007; (3):CD003419.
  11. Asvold BO, Bjoro T, Nilsen TI, Vatten LJ. Association between blood pressure and serum thyroid-stimulating hormone concentration within the reference range: a population-based study. J Clin Endocrinol Metab. 2007 Mar; 92 (3):841–845.
  12. Dillmann WH. Cellular action of thyroid hormone on the heart. Thyroid. 2002;12 (6):447–452.
  13. Kiss E, Jakab G, Kranias EG, Edes I. Thyroid hormone-induced alterations in phospholamban protein expression. Regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res. 1994;75 (2):245–251.
  14. Vitale G, Galderisi M, Lupoli GA et al. Left ventricular myocardial impairment in subclinical hypothyroidism assessed by a new ultrasound tool: pulsed tissue Doppler. J Clin Endocrinol Metab. 2002;87 (9):4350–4355.
  15. Biondi B, Fazio S, Palmieri EA et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 1999;84 (6):2064–2067.
  16. Monzani F, Di Bello V, Caraccio N et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 2001;86 (3):1110–1115.
Blankova Z.N., Seredinina E.M., Ageev F.T. Effect of therapy with levothyroxine on clinical, hemodynamic and neurohumoral status of patients with heart failure in combination with subclinical hypothyroidism. 2011;12(1):18-22.

To access this material please log in or register

Register Authorize
Ru En